Sir Greg Winter
Sir Gregory Winter is a molecular biologist who pioneered the field of protein engineering. He is best known for developing technologies that have led to several blockbuster antibody drugs, including Humira, Keytruda, Avastin, and Herceptin. For his work on antibody phage display he shared the Nobel Prize in Chemistry in 2018. In parallel with his research, he has immersed himself in commercial matters, including the filing of patents, the development of licensing strategies and the founding of start-up companies. Now in retirement, he serves a non-executive Director of the company Bicycle Therapeutics (NASDAQ: BCYC), which he founded for the development of small bicyclic peptides as antibody mimics.